synonymous with adenocarcinoma, is expressed in only 80-90% of cases and is commonly 70 expressed in neuroendocrine tumours. (14, 16) Immunohistochemistry can only be meaningfully 71 interpreted in a detailed morphological context. 72 
73
Sampling challenges in advanced NSCLC 74 75 The analysis of lung cancer tissue is particularly challenging as primary lung tumours often 76 show much lower tumour cellularity than other tumour types. Even with macroscopic 77 selection of areas of frank carcinoma the tumour purity (the fraction of a given region 78 containing tumour cells) can often be <20% because of the high proportion of stromal cells, 79 lymphocytic infiltration and necrosis (unpublished observations from the UK Lung TRACERx 80 longitudinal cohort study). (17) . 81 
82
This challenge is compounded by the nature of the specimen types routinely received by 83 histopathology and molecular diagnostics laboratories. Presentation with metastatic disease 84 is common and only a small proportion of patients with NSCLC undergo curative surgical 85 resection. (18) EGFR gene, with detection of L858R and deletions in exon 19 the clinical priority as these 139 determine sensitivity to first and second generation TKIs. (36) The T790M mutation in exon 20 140 results in resistance to these therapies. (37) Sensitive assays suggest that tumour clones 141 harbouring the T790M mutation are often detectable prior to initiation of a first generation 142 TKI but can also occur by genetic evolution in T790M mutation negative drug tolerant cells in 143 response to treatment. (38) (39) (40) Identification of this resistance mutation is more critical 144 following the development of the third generation EGFR TKIs active against T790M mutation 145 positive NSCLCs. (41, 42) But whether these T790M resistant clones pre-exist or evolve in 146 response to treatment may have clinical implications with differing sensitivities to third 147 generation TKIs. (40) The capacity for tumours to evolve in response to first generation TKIs 148 results in an additional diverse array of mechanisms of resistance such as amplification of 149 MET, selection for PIK3CA or BRAF mutations and transformation to a small cell 150 phenotype. (43) Clearly, cancer evolution and selection of resistant subclones is not restricted 151 to first generation TKIs. This is highlighted by recent reports of the emergence of T790M 152 mutation negative disease and the development of novel secondary EGFR resistance 153 mutations (C797S) after treatment of T790M mutation positive patients with third 154 generation TKIs. (44, 45) 155 156 EGFR mutation testing
157
The nature of EGFR sensitizing mutations, being single nucleotide variants (SNV) or short 158 deletions, lends themselves to molecular analysis of formalin fixed small samples which 159 contain fragmented DNA. (46) There are a variety of methods to detect EGFR mutations 160 including conventional Sanger sequencing, amplification refractory mutations systems 161 (ARMS), restriction fragment length polymorphisms and more recently as part of targeted 162 NGS panels. (47, 48) Reporting the limitations of an assay along with the result is critical for 163 clinical interpretation. Bi-directional Sanger sequencing without a mutation enrichment step 164 has a lower limit of detection of 10-25% of total DNA meaning that the use of samples with 165 low tumour cellularity can result in false negative mutation calls. Consequently the use of 166 methods that can detect mutations in low tumour cellularity samples (<10%) is 167 recommended. Polymerase chain reaction (PCR) based ultra sensitive and NGS methods can 168 generate artefact mutations leading to false positive results. However techniques, such as 169 duplex sequencing, are being developed to overcome the inherent error rate in sequencing 170 technologis (49) Formalin fixed samples are particularly prone to DNA damage and display 171 disproportionate levels of C>T/G>A changes in the 1-10% allele frequency range which can result in false positive mutation calls. (50) Publication of clinical trials results on response to 173 EGFR TKI in patients with real but less common EGFR mutations can help guide clinical 174 decision-making. (51) Detection of EGFR mutations as part of a WES or WGS analysis allows 175 multiple driver mutations to be queried simultaneously but the performance of 176 bioinformatics tools to call mutations from NGS data varies. Such complexities need to be 177 considered as these technologies are increasingly adopted into mainstream clinical 178 practice. (52) (53) (54) 179 180 EGFR mutations, resistance and tumour heterogeneity
181
There are very few reports of discordance of EGFR mutation status between primary disease 182 and metastatic sites and these may be due to technical limitations of the assays used. (55) Loss 183 of the EGFR mutation was not a mechanism seen in seminal studies. (43) Studies looking at the 184 extent of intra tumour heterogeneity (ITH) in early lung cancer have shown EGFR to be 185 exclusively a clonal event prevalent throughout the tumour. (56, 57) As resistance to EGFR TKI is 186 usually due to acquisition of secondary mutations in EGFR or other driver genes the key based chemotherapy. (59, 62, 63) Subsequently other rare fusion genes have been identified 202 involving ROS1, with similar exquisite sensitivity to kinase inhibition, (64) but also RET and 203 NTRK where objective response rates are lower. (65, 66) 
209
NSCLC cancer this is typically a balanced translocation with the ubiquitously highly expressed 210 EML4 gene, (58) although rarely other partner genes may be involved. (67, 68) Expression of the 211 chimeric protein leads to upregulation of mitogenic signalling through the RAS/RAF pathway 212 and interruption of this pathway by ALK inhibitors causes cancer cell death and tumour 213 regression. (62) ALK-mutated tumours often show unusual features on conventional 214 microscopy, such as cribriform growth patterns and 'signet ring' cells with large vacuoles, (69) 215 but this is not sufficiently sensitive or specific to guide treatment.
217
The first widely adopted test for ALK-driven tumours was FISH (fluorescence in situ 218 hybridisation), approved by the FDA (US Food and Drug Administration) in 2011. (70) FISH is a 219 technically demanding method, requiring specialised equipment and experienced 
227
In 2015, an immunohistochemistry method was approved by the FDA. This approach is 228 simpler in principle, using an antibody stain to detect abnormal ALK antigen expression.
229
However, currently available antibodies do not give a strong signal and so an additional 230 signal amplification steps needs to be employed. This places the test beyond the capacity of 231 many small labs. Nonetheless, the modified test is cheaper than FISH, easier to interpret, 232 and has the theoretical advantage of additionally detecting ALK expression following rare 233 atypical rearrangements. After much investigation, recent studies suggest 234 immunohistochemistry can be an adequate stand-alone diagnostic, showing extremely high 235 concordance with FISH. (71) UK guidelines do not dictate which test should be applied, and 236 practices vary regionally, though FISH is still often regarded as the 'gold standard' and is 237 considered the definitive test in the US. (48) As our understanding of tumour taxonomy and 238 genotypes advances, it seems inevitable that some form of NGS platform will become the 239 clinical standard for gene fusion detection. (72) These methods have the potential to detect 240 ALK (and other) rearrangements in either a targeted panel or a WES or WGS approach. (73, 74) 241 (72) 242 243 ALK fusion genes, resistance and tumour heterogeneity 244 ALK fusion genes are considered to be clonal events with minimal discordance between 245 primary and metastatic lesions. (75) They were considered to be mutually exclusive with EGFR 246 mutations however recent reports suggests a small minority of tumours can contain both 247 ALK and EGFR positive clones. (76) (77) (78) The mechanisms of resistance seen following ALK 248 inhibitor therapy again demonstrate tumour evolution with secondary mutations in ALK, ALK 249 copy number gain, secondary driver mutations in other genes and outgrowth of ALK fusion 250 gene negative clones reported. (79) (80) (81) (82) Consequently contemporaneous sampling of therapies. (83, 84) The use of next generation sequencing to simultaneously assay multiple 260 oncogenic drivers is attractive because less DNA is required compared to multiple individual 261 assays, there is a reduction in hands-on laboratory time, and complex FISH analysis for 262 detection of fusion genes may be avoided. A recent NGS approach used an amplicon based 263 approach to assay 14 genes used only 50ng of DNA from FFPE samples. (85) This study 264 provided a comprehensive assessment of the spectrum of mutations, and co-occurrence of 265 mutations, in adenocarcinoma and squamous cell carcinomas with detection turn around 266 times of less than two weeks. These studies and those of The Cancer Genome Atlas highlight 267 the inter-patient molecular heterogeneity of NSCLC ( Figure 2 ). Even within these molecular 268 cohorts intra-tumour heterogeneity could have significant effects on outcome as 269 exemplified by a recent study showing that the clonality of FGFR amplification is an 270 important predictor of response to FGFR inhibition. (86) A deeper understanding of the clonal 271 or subclonal nature of driver events in NSCLC from sufficiently powered studies, is still 272 awaited. Recruitment of patients with rare mutations to molecularly stratified trials is 273 challenging, (87) and some advocate that modifications to existing paradigms in drug development are required in the era of genomic studies and precision medicine. (88) 
292
Recent randomised trials have shown activity of PD1 and PDL1 targeting antibodies in 293 squamous and non-squamous NSCLC. (92) (93) (94) (95) (96) In most instances these agents have shown 294 greater activity in patients whose tumour expresses PDL1 when tested using IHC. However 295 durable responses are seen in patients without PDL1 expression. This is unsurprising given 296 the technical and spatial heterogeneity of PDL1 expression in NSCLC, which hampers its use 297 as a predictive biomarker. (97) (98) (99) Studies of the expression of PDL1 on APCs in NSCLC are also 298 contradictory with respect to any correlation with tumour infiltration of the effector CD8 299 positive T cells. (89, 97, 98) 
301
Regulation of PDL1 expression is complex and controlled by both cell intrinsic and cell 302 extrinsic factors. (100) This means that oncogene driven expression of PDL1 can result in 303 increased expression in the absence of significant underlying immunogenicity. (101) This 304 underlying immunogenicity is thought to be a result of non-synonymous SNVs which 305 generate neoantigens, mutated proteins, recognised by the TIL population. (102, 103) The 306 number of neoantigens harboured by a tumour could act as a potential biomarker for 307 immunotherapy although there are technical challenges inherent with such complex 308 assessments. Recent data also suggest that neo-antigen intratumour heterogeneity may also 309 be associated with altered checkpoint inhibitor response, which may further complicate the 310 use of such assays in a clinical setting. (104) 
312
The advent of immunotherapy presents additional challenges for molecular diagnostics in 
331
Lung Matrix Trial (NLMT) (NCT02664935) a phase II umbrella study with both targeted 332 therapy and immunotherapy arms for patients who have progressed on first line therapy. (107) 
333
In comparison, the Lung-MAP (NCT02154490) and SAFIR02 Lung trial (NCT02117167) are 334 umbrella studies, outside of the UK, for patients with NSCLC where recruitment is preceded 335 by molecular stratification ( 
363
Unique to NLMT is the need to determine wild type status of some genes for eligibility to 364 certain arms. Patients recruited to the CDK4/6 inhibitor palbociclib arm must have wildtype 365 retinoblastoma 1 protein (RB1) in addition to deficiencies in cell cycle regulation. The 366 determination of wildtype status requires a pre-sequencing assessment of tumour cellularity 367 to determine appropriate sequencing depth. However there can be significant discordance 368 between pathologist assessments of this. (108) Clearer guidance and online training should 369 ensure more concordance for visual assessment, whilst digital solutions may provide a useful 370 alternative. A number of computational methods exist to assess tumour purity and control 371 for both stromal cell admixture and cancer cell ploidy in DNA samples from next generation 372 sequencing data. (109, 110) 
374
Extremes of GC nucleotide content in certain genes (RB1 and FGFR3) can result in an 375 increased number of sequencing failures. Additional probe coverage in the targeted panel 376 and correction for GC content in the data processing stage will improve results for these 377 difficult to sequence regions. Following these incremental improvements at each step of the 378 molecular pathology workflow we have shown that the number of successfully sequenced 379 samples that would allow recruitment to the NLMT increased and there has also been an 380 increase in identification of potentially actionable mutations that would permit recruitment 381 to trials other than the NLMT. challenge facing clinicians and pathologists is the need for ever greater amounts of 389 information from diminishing amounts of tissue. It is therefore imperative that the quality of 390 diagnostic samples in the advanced NSCLC setting is of the highest order. How best to 391 achieve this represents a challenge for health service providers that has received very little 392 attention thus far. However the spectre of ITH and cancer evolution means that sampling 393 bias and the presence of subclonal driver mutations, causing resistance to therapy, are likely 394 to hinder clinical benefit of targeted therapeutics. (111, 112) The UK Lung TRAcking Cancer
395
Evolution through Therapy trial (NCT01888601) is currently characterizing the extent of ITH 396 in early surgically resected NSCLC and with longitudinal follow-up aims to determine the 397 origins of tumour subclones contributing to relapse. (17) There is evidence from other tumour 398 types of parallel evolution, acquisition of mutations in the same gene or signalling pathway 399 in distinct subclones, that may highlight an 'evolutionary bottle neck' that could be an 400 Achilles heel for subsequent cancer therapy. (113) (114) (115) Clonal analyses of a drug target and 401 putative resistance events, whether they are present in all tumor cells or only a proportion, 402 may affect the response rate and progression free survival times on targeted therapy and 403 this is being addressed in clinical trials including the DARWIN studies (NCT02314481, 404 NCT02183883). Ultimately it may be that only through 'warm' autopsy studies, where 405 subclonal phylogenetic structures can be determined through sampling multiple sites of 406 disease, that effective strategies to forestall cancer evolution can be elucidated. (116) 407 408 Circulating biomarkers
409
The use of minimally invasive methods to detect mutations in circulating cell-free DNA 410 (cfDNA) or 'liquid biopsies' offers the potential to obtain a mutation call in a patient where 411 an invasive biopsy may not be feasible. As tumour DNA from all sites of disease has the 412 potential to enter the blood stream it may also be a better reflection of tumour 413 heterogeneity than a single biopsy. (117, 118) The use of cfDNA to detect resistance mechanisms 414 in patients treated with EGFR TKIs, often prior to radiographic progression, has been 415 demonstrated. (45, 119, 120) This has resulted in the development and approval of a commercially 416 available assay of cfDNA in plasma that can detect a spectrum of EGFR mutations in 417 including the T790M mutation amenable to targeting with third generation TKIs.
419
Circulating tumour cells (CTCs) are tumour cells that can be isolated from the peripheral 420 blood and are a complementary circulating biomarker to cfDNA. CTCs are a versatile tool, 421 cell enumeration can be prognostic, immunohistochemistry permits further characterization, 422 single cell DNA or RNA sequencing is possible and tumour xenografts can be generated to 423 assess drug response. (121) (122) (123) (124) (125) However at present the complexity of separation from other 424 cells in the peripheral circulation and the need to process samples promptly for functional or 425 genomic studies results in greater expense in comparison to cfDNA analysis. Circulating 426 biomarkers will make a significant impact on cancer management in the near future and 427 readers are directed to more extensive reviews focusing on CTCs, cfDNA and other 428 circulating nucleotides. (121, (126) (127) (128) (129) (130) The proportions presented are based on estimates from the referenced studies and data sources, including the Stratified Medicine Programme 2 (unpublished data). (2, 3, 85, 131) These studies examine SNVs, copy number variants and gene fusion products using different sequencing technologies and sequencing depth resulting in inter-study variation and therefore the data is presented in aggregate form and represents an approximation. CCGA (Cell cycle genomic aberration); loss of Cyclin-Dependent Kinase Inhibitor 2A or amplification of Cyclin-Dependent Kinase 4 or Cyclin D1 in the presence of wildtype RB1. (107) EGFR, Epidermal growth factor receptor; LKB1, Liver Kinase B1; ALK, anaplastic lymphoma kinase; MET, MET Proto-Oncogene, Receptor Tyrosine Kinase; FGFR, fibroblastic growth factor receptor; NRAS, neuroblastoma RAS viral (v-ras) oncogene homolog; DDR2 Discoidin Domain Receptor Tyrosine Kinase 2; AKT1, v-akt murine thymoma viral oncogene homolog 1; PTEN, Phosphatase And Tensin Homolog; PIK3CA, phosphoinositide-3-kinase, catalytic, α polypeptide; BRAF, v-raf murine sarcoma viral oncogene homolog B1; ERBB2, human epidermal growth factor receptor 2; KRAS, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; TP53, Tumor Protein P53. 
